Carilax250 mg

Carilax 250 mg is indicated for- The relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Sedation and decrease anxiety in patients with severe pain. Used as an adjunct in physical therapy in injuries.

Locally acting Skeletal Muscle Relaxants

Carilax 250 mg is a GABA-A receptor indirect agonist with CNS chloride channel conductance effect. GABA receptor agonists typically produce sedative effect and may also cause other effects such as anxiolytic, anticonvulsant and muscle relaxant. Metabolite of Carilax 250 mg, Meprobamate, has anxiolytic and sedative properties. Carilax 250 mg decreases the impulses from brain and spinal cord to the muscle. This causes the muscle to relax and hence decrease the spasm. It has no direct action on muscle itself.

Adults (18 years and older): The recommended dose of Carilax 250 mg is 250 mg three times daily and at bedtime (4 times daily). The recommended maximum duration of Carilax 250 mg use is up to two or three weeks. Caution should be taken in patients with renal and hepatic impairment and also with reduced CYP2C19 activity.

Adults (18 years and older): The recommended dose of Carilax 250 mg is 250 mg three times daily and at bedtime (4 times daily). The recommended maximum duration of Carilax 250 mg use is up to two or three weeks. Caution should be taken in patients with renal and hepatic impairment and also with reduced CYP2C19 activity.

Caution should be exercised with patients who take other CNS depressants (eg. alcohol, benzodiazepines, opioids, tricyclic antidepressants) with Carilax 250 mg. Co-administration of CYP2C19 inhibitors (Omeprazole, Fluvoxamine) with Carilax 250 mg could result in increased exposure of Carilax 250 mg. Co-administration of CYP2C19 inducers (Rifampin) with Carilax 250 mg could result in decreased exposure of arisoprodol.

Carilax 250 mg is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate.

Common side effects are drowsiness, dizziness and headache.

Pregnancy category C. Maternal use of Carilax 250 mg may lead to reduced or less effective infant feeding (due to sedation) and/or decresed milk production. Caution should be exercised when Carilax 250 mg is administered to a nursing woman.

Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery. Additive sedative effects when used with other CNS depressants including alcohol. Cases of Drug Dependence, Withdrawal, and Abuse. Seizures

Overdosage of Carilax 250 mg commonly produces CNS depression. Death, coma, respiratory depression, hypotension, seizures have been reported with Carilax 250 mg overdosage. Basic life support measures should be instituted in Carilax 250 mg overdose. Induced emesis is not recommended due to the risk of CNS and respiratory depression. Gastric lavage should be considered soon after ingestion (within one hour). Circulatory support should be administered with volume infusion and vasopressor agents if needed. Seizures should be treated with intravenous benzodiazepines and the reoccurrence of seizures may be treated with phenobarbital. In cases of severe CNS depression, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support.

Store in cool and dry place at room temperature 20°-25°C, away from direct light. Keep out reach of children.

Locally acting Skeletal Muscle Relaxants

Carilax 250 mg is a GABA-A receptor indirect agonist with CNS chloride channel conductance effect. GABA receptor agonists typically produce sedative effect and may also cause other effects such as anxiolytic, anticonvulsant and muscle relaxant. Metabolite of Carilax 250 mg, Meprobamate, has anxiolytic and sedative properties. Carilax 250 mg decreases the impulses from brain and spinal cord to the muscle. This causes the muscle to relax and hence decrease the spasm. It has no direct action on muscle itself.

Pregnancy category C. Maternal use of Carilax 250 mg may lead to reduced or less effective infant feeding (due to sedation) and/or decresed milk production. Caution should be exercised when Carilax 250 mg is administered to a nursing woman.